AAPL   318.68 (+0.14%)
MSFT   181.19 (-0.12%)
FB   224.68 (-0.35%)
GOOGL   1,422.61 (+0.31%)
AMZN   2,409.47 (+0.35%)
NVDA   342.91 (+1.01%)
CGC   17.59 (-19.02%)
BABA   198.52 (-0.49%)
MU   46.66 (+0.41%)
GE   6.51 (-3.98%)
TSLA   817.27 (+1.42%)
AMD   52.23 (+0.95%)
T   30.61 (-1.45%)
ACB   14.04 (-8.47%)
F   5.64 (-3.59%)
GILD   75.05 (-0.36%)
DIS   114.49 (-1.94%)
NFLX   413.30 (-0.03%)
BAC   24.40 (-1.85%)
BA   144.04 (-3.86%)
AAPL   318.68 (+0.14%)
MSFT   181.19 (-0.12%)
FB   224.68 (-0.35%)
GOOGL   1,422.61 (+0.31%)
AMZN   2,409.47 (+0.35%)
NVDA   342.91 (+1.01%)
CGC   17.59 (-19.02%)
BABA   198.52 (-0.49%)
MU   46.66 (+0.41%)
GE   6.51 (-3.98%)
TSLA   817.27 (+1.42%)
AMD   52.23 (+0.95%)
T   30.61 (-1.45%)
ACB   14.04 (-8.47%)
F   5.64 (-3.59%)
GILD   75.05 (-0.36%)
DIS   114.49 (-1.94%)
NFLX   413.30 (-0.03%)
BAC   24.40 (-1.85%)
BA   144.04 (-3.86%)
AAPL   318.68 (+0.14%)
MSFT   181.19 (-0.12%)
FB   224.68 (-0.35%)
GOOGL   1,422.61 (+0.31%)
AMZN   2,409.47 (+0.35%)
NVDA   342.91 (+1.01%)
CGC   17.59 (-19.02%)
BABA   198.52 (-0.49%)
MU   46.66 (+0.41%)
GE   6.51 (-3.98%)
TSLA   817.27 (+1.42%)
AMD   52.23 (+0.95%)
T   30.61 (-1.45%)
ACB   14.04 (-8.47%)
F   5.64 (-3.59%)
GILD   75.05 (-0.36%)
DIS   114.49 (-1.94%)
NFLX   413.30 (-0.03%)
BAC   24.40 (-1.85%)
BA   144.04 (-3.86%)
AAPL   318.68 (+0.14%)
MSFT   181.19 (-0.12%)
FB   224.68 (-0.35%)
GOOGL   1,422.61 (+0.31%)
AMZN   2,409.47 (+0.35%)
NVDA   342.91 (+1.01%)
CGC   17.59 (-19.02%)
BABA   198.52 (-0.49%)
MU   46.66 (+0.41%)
GE   6.51 (-3.98%)
TSLA   817.27 (+1.42%)
AMD   52.23 (+0.95%)
T   30.61 (-1.45%)
ACB   14.04 (-8.47%)
F   5.64 (-3.59%)
GILD   75.05 (-0.36%)
DIS   114.49 (-1.94%)
NFLX   413.30 (-0.03%)
BAC   24.40 (-1.85%)
BA   144.04 (-3.86%)
Log in

LON:SARSareum Share Price, Forecast & News

GBX 0.71
-0.06 (-7.79 %)
(As of 05/29/2020 11:07 AM ET)
Add
Compare
Today's Range
0.70
Now: GBX 0.71
0.77
50-Day Range
0.34
MA: GBX 0.67
0.87
52-Week Range
0.03
Now: GBX 0.71
1.10
Volume9.00 million shs
Average Volume6.23 million shs
Market Capitalization£21.81 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Sareum Holdings plc engages in the discovery and development of therapeutic drugs to treat cancer and autoimmune diseases. It develops therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1223-497700

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Outstanding Shares3,071,360,000
Market Cap£21.81 million
Next Earnings DateN/A
OptionableNot Optionable

Receive SAR News and Ratings via Email

Sign-up to receive the latest news and ratings for SAR and its competitors with MarketBeat's FREE daily newsletter.

Sareum (LON:SAR) Frequently Asked Questions

How has Sareum's stock been impacted by COVID-19 (Coronavirus)?

Sareum's stock was trading at GBX 0.31 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SAR stock has increased by 132.8% and is now trading at GBX 0.71. View which stocks have been most impacted by Coronavirus.

Has Sareum been receiving favorable news coverage?

Media coverage about SAR stock has been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Sareum earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View the latest news aboutSareum.

Who are some of Sareum's key competitors?

What other stocks do shareholders of Sareum own?

Who are Sareum's key executives?

Sareum's management team includes the following people:
  • Dr. Tim J. Mitchell, Founder, CEO & Exec. Director (Age 59)
  • Dr. John C. Reader Ph.D., Founder, Chief Scientific Officer & Exec. Director (Age 52)
  • Tony Bunn FCMA, Sec.

What is Sareum's stock symbol?

Sareum trades on the London Stock Exchange (LON) under the ticker symbol "SAR."

How do I buy shares of Sareum?

Shares of SAR and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Sareum's stock price today?

One share of SAR stock can currently be purchased for approximately GBX 0.71.

How big of a company is Sareum?

Sareum has a market capitalization of £21.81 million.

What is Sareum's official website?

The official website for Sareum is www.sareum.co.uk.

How can I contact Sareum?

Sareum's mailing address is Unit 2A Langford Arch, London Road, Pampisford, CAMBRIDGE, CB22 3FX, United Kingdom. The company can be reached via phone at +44-1223-497700.

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.